Start Over

Increased expression of CEP72 predicts poor prognosis in multiple myeloma.

Authors :: Guo D
Lu J
Ji H
Lin Z
Hong L
Huang H
Liu H
Source :: International journal of laboratory hematology [Int J Lab Hematol] 2023 Jun; Vol. 45 (3), pp. 317-327. Date of Electronic Publication: 2023 Feb 13.
Publication Year :: 2023
Abstract: Introduction: Multiple myeloma (MM) is a fatal hematological malignancy and does not have adequate prognostic indicators. Previous studies indicate that CEP72 is closely related to tumorigenesis and tumor progression. However, the expression and function of CEP72 in multiple myeloma have yet to be elucidated.<br />Methods: In this study, we explored the correlation between CEP72 expression and clinicopathological characteristics as well as the impacts of CEP72 expression on the survival of MM patients. In addition, PPI, GSEA and Chemotherapy drug resistance analysis identified the possible mechanism.<br />Results: CEP72 is overexpressed in both MM patients and MM cell lines. Clinically, patients in the CEP72 <superscript>high</superscript> subgroup were significantly older than those in the CEP72 <superscript>low</superscript> subgroup (p = 0.003). Up-regulation of CEP72 was related to poor overall survival and event-free survival. PPI network showed that CEP72 was related to PCM1, KIZ, OFD1, etc. GSEA analysis showed that CEP72 was enriched in cell cycle, oocyte meiosis, protein export, lysosome and N-glycan biosynthesis pathways. Drug resistance analysis indicated that there was a positive correlation between the CEP72 expression and the IC50 values of 6-mercaptopurine, 8-chloro-adenosine, clofarabine, fludarabine and allopurinol.<br />Conclusion: High CEP72 expression was a poor prognostic factor in patients diagnosed with multiple myeloma.<br /> (© 2023 John Wiley & Sons Ltd.)